AAP Grand Rounds Subscribe to Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ballinger, S. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ballinger, S. H.
Related Collections
Right arrow Rheumatology

AAP Grand Rounds 4:55-56 (2000)
© 2000 American Academy of Pediatrics

RHEUMATOLOGY/METABOLISM

Oral Bisphosphonate Effective Therapy for Osteoporosis

Source: Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000;43:1960–1966.

The first 20% of the full text of this article appears below.

The effect of an oral bisphosphonate on bone mass in children with diffuse connective tissue disease was evaluated in this prospective, multicenter Italian trial. Thirty-eight children (26 females) with low bone mass secondary to a variety of rheumatologic conditions were treated for 1 year with alendronate (5mg/d, wt <20kg; 10mg/d, wt >20kg), an oral bisphosphonate. All patients met the criteria of a spine bone mass density (BMD) Z-score of less than –1.5 (nl 0 or above) and one of the following: 1) history of bone fragility fractures (n=5); 2) history of continuous glucocorticoid therapy for at least 6 months (n=30); 3) both a history of fractures and steroid therapy (n=3). A control group of patients with similar . . . [Full Text of this Article]

Susan H. Ballinger, MD, FAAP
Rheumatology, James Whitcomb Riley Hospital, Indianapolis, IN

 





HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Academy of Pediatrics.